Effect of A Multimodal Exercise Intervention on Chemotherapy Uptake in Newly Diagnosed Pediatric and AYA Sarcoma Patients

Prior treatment

• More than 90 days from initiation of first-line systemic therapy.

Other illness

• Presence of a severe medical condition or psychiatric condition or medications that would preclude participation of the study intervention, as determined by the patient's provider and study clinician.

Age

• \< 12 or \>39 years old

Other

• Unable to provide consent
• Unable to read or understand English or Spanish
• Oxygen-dependent
• Unable to walk 2 blocks without assistance (excluding canes)
• Unstable bone metastases

• Diagnosis of Sarcoma
• Pediatric or AYA (12-39 years old)
• Able to provide written informed consent
• Able to speak, read, and understand English or Spanish
• Initiating first-line systemic therapy (Doxorubicin, Ifosfamide, Gemcitabine, Docetaxel, Trabectedin, Vincristine, Irinotecan, Temozolomide, Topotecan, Etoposide, Dacarbazine, Pazopanib, Tazemetostat, Imatinib, Sunitinib, Pembrolizumab, Nivolumab, Ipilumumab, Regorafenib, Atezulimumab). Participants can be enrolled up to 90 days after starting firstline systemic therapy.
• Approval from a medical oncology provider to participate.
• Having not consistently (not equal to or more than 50% of the time) engaged in more than 90 minutes of moderate or 45 minutes of vigorous physical activity per week over the past 3 months
• Having not consistently engaged in resistance training 2 or more days per week over the past 3 months